These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 6327902

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340: incidence and potential for virus neutralization.
    Yao QY, Rowe M, Morgan AJ, Sam CK, Prasad U, Dang H, Zeng Y, Rickinson AB.
    Int J Cancer; 1991 Apr 22; 48(1):45-50. PubMed ID: 1850382
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. A preliminary study on the immunogenicity in rabbits and in human volunteers of a recombinant vaccinia virus expressing Epstein-Barr virus membrane antigen.
    Gu S, Huang T, Miao Y, Ruan L, Zhao Y, Han C, Xiao Y, Zhu J, Wolf H.
    Chin Med Sci J; 1991 Dec 22; 6(4):241-3. PubMed ID: 1667485
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Identification of GLA/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits.
    Heeke DS, Lin R, Rao E, Woo JC, McCarthy MP, Marshall JD.
    Vaccine; 2016 May 17; 34(23):2562-9. PubMed ID: 27085175
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Preparation and efficacy of antiherpes type 1 and 2 subunit vaccines.
    Kavaklova L, Dundarov S, Andonov P, Bakalov B, Dundarova D, Brodvarova I.
    Acta Virol; 1986 Sep 17; 30(5):402-10. PubMed ID: 2878588
    [Abstract] [Full Text] [Related]

  • 31. Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate.
    Goetsch L, Plotnicky-Gilquin H, Champion T, Beck A, Corvaïa N, Stâhl S, Bonnefoy JY, Nguyen TN, Power UF.
    Vaccine; 2000 Jun 01; 18(24):2735-42. PubMed ID: 10781861
    [Abstract] [Full Text] [Related]

  • 32. Antigenic analysis of the Epstein-Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccine.
    Emini EA, Schleif WA, Armstrong ME, Silberklang M, Schultz LD, Lehman D, Maigetter RZ, Qualtiere LF, Pearson GR, Ellis RW.
    Virology; 1988 Oct 01; 166(2):387-93. PubMed ID: 2845652
    [Abstract] [Full Text] [Related]

  • 33. Epstein-Barr virus vaccines.
    Morgan AJ.
    Vaccine; 1992 Oct 01; 10(9):563-71. PubMed ID: 1323899
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. In vivo induction of anti-herpes simplex virus immune response by type 1 antigens and lipid A incorporated into liposomes.
    Naylor PT, Larsen HS, Huang L, Rouse BT.
    Infect Immun; 1982 Jun 01; 36(3):1209-16. PubMed ID: 6284643
    [Abstract] [Full Text] [Related]

  • 37. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT, Marshall JD, Dorwart MR, Heeke DS, Rao E, Tummala P, Yu L, Cohen GH, Eisenberg RJ, Sloan DD.
    J Virol; 2017 May 01; 91(9):. PubMed ID: 28228587
    [Abstract] [Full Text] [Related]

  • 38. Purification and characterization of Epstein-Barr virus gp340/220 produced by a bovine papillomavirus virus expression vector system.
    Madej M, Conway MJ, Morgan AJ, Sweet J, Wallace L, Qualtiere LF, Arrand JR, Mackett M.
    Vaccine; 1992 May 01; 10(11):777-82. PubMed ID: 1332270
    [Abstract] [Full Text] [Related]

  • 39. Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene.
    Weijer K, Pfauth A, van Herwijnen R, Jarrett O, Meloen RH, Tomee C, Osterhaus AD.
    Vaccine; 1993 May 01; 11(9):946-56. PubMed ID: 7692683
    [Abstract] [Full Text] [Related]

  • 40. Lipid vesicle-entrapped influenza A antigen modulates the influenza A-specific human antibody response in immune reconstituted SCID-human mice.
    Walker W, Brewer JM, Alexander J.
    Eur J Immunol; 1996 Jul 01; 26(7):1664-7. PubMed ID: 8766578
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.